Symrise AG (OTCMKTS:SYIEY – Get Rating) – Analysts at Jefferies Financial Group boosted their FY2022 EPS estimates for Symrise in a report released on Wednesday, September 14th. Jefferies Financial Group analyst C. Counihan now forecasts that the company will post earnings of $0.86 per share for the year, up from their previous estimate of $0.82. The consensus estimate for Symrise's current full-year earnings is $0.82 per share. Jefferies Financial Group also issued estimates for Symrise's FY2023 earnings at $0.99 EPS.
Get Symrise alerts:Separately, Berenberg Bank dropped their target price on shares of Symrise from €119.00 ($121.43) to €114.00 ($116.33) and set a "hold" rating on the stock in a research note on Tuesday, July 19th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $117.00.
Symrise Stock Down 0.6 %
Symrise stock opened at $24.70 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.17 and a current ratio of 2.04. Symrise has a fifty-two week low of $24.53 and a fifty-two week high of $37.21. The firm's 50-day simple moving average is $27.23 and its 200 day simple moving average is $27.80.Symrise Company Profile
(Get Rating)
Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients. It operates through two segments, Taste, Nutrition & Health, and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and flavor solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for aqua feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.
Further Reading
- Get a free copy of the StockNews.com research report on Symrise (SYIEY)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.